Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
BURLINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root caus
Structure CEO on the competitive landscape for oral GLP-1 drugs
06:17pm, Thursday, 05'th Dec 2024
Raymond Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk its oral GLP-1 offerings.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the design of its pivotal Phase 3 LUCIDITY clinical trial f
After Crashing 27% in the Past Month, Is Viking Therapeutics Stock a Bargain Buy Right Now?
08:27am, Tuesday, 03'rd Dec 2024
There's a growing number of companies entering the weight loss space, focusing on GLP-1 drugs which can be game changers for their businesses. And one of them is Viking Therapeutics (VKTX -2.70%), whi
Fmr. FDA Commissioner on how Trump could impact GLP-1 industry
06:03pm, Monday, 02'nd Dec 2024
Dr. Scott Gottlieb joins 'Fast Money' to talk how a Trump administration could impact the GLP-1 drug industry.
Millions more Americans might get access to GLP-1 drugs
04:21pm, Tuesday, 26'th Nov 2024
A new proposal by the Biden administration would see obesity drugs covered under Medicare and Medicaid. Transcript: Conway Gittens: The Dow and the S&P 500 closed at fresh record highs on Tuesday as i
Biden administration plans to expand coverage of GLP-1 drugs for Americans with Medicare & Medicaid
11:33am, Tuesday, 26'th Nov 2024
CNBC's Bertha Coombs joins 'Squawk on the Street' to report on Biden's administration plan to expand coverage of GLP-1 drugs for Americans with Medicare and Medicaid.
Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs
09:20am, Tuesday, 26'th Nov 2024
Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and more GLP-1 drugs expected to generate multi-hundreds of billions of revenues in the years to come KELO
Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled
09:00am, Monday, 25'th Nov 2024
DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC / ACCESSWIRE / November 25, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Compa
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist.
Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
09:10am, Thursday, 14'th Nov 2024
World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / November 14, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the
Phase 2b ACCESS study designed to evaluate multiple doses up to 120 mg of GSBR-1290 over 36 weeks Comprehensive development program also includes Phase 2 ACCESS II study to evaluate even higher do
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
09:20am, Wednesday, 13'th Nov 2024
DehydraTECH clinical test article manufacturing has been completed KELOWNA, BC / ACCESSWIRE / November 13, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global i
After two weeks of treatment, GZR18 tablets resulted in an average weight reduction of up to 4.16%, with continued weight loss observed even after discontinuation. The pharmacokinetic profile support
Global Partners LP Common Units (GLP) Q3 2024 Earnings Call Transcript
12:03pm, Friday, 08'th Nov 2024
Global Partners LP Common Units (NYSE:GLP ) Q3 2024 Earnings Conference Call November 8, 2024 10:00 AM ET Company Participants Eric Slifka - President & CEO Gregory Hanson - CFO Mark Romaine - COO Sea
